Target and Technology
ASG-15ME is an antibody-drug conjugate (ADC) that targets SLITRK6, a protein found in urothelial cancer and other cancer types, including lung, breast and glioblastoma. It is composed of a monoclonal antibody targeted to SLITRK6 attached to our synthetic cell-killing agent, monomethyl auristatin E (MMAE), a microtubule-disrupting agent, using our proprietary linker technology. ASG-15ME is the first agent to target SLITRK6. We are co-developing ASG-15ME with Astellas. Preclinical data demonstrate that ASG-15ME effectively binds to target cells, internalizes, and induces cell-killing activity.
ADC technology combines the specificity of monoclonal antibodies, innovative linker systems, and the cell killing power of potent cytotoxic agents to treat cancer. Using our proprietary industry-leading technology, we are able to optimize each ADC to potentially improve outcomes for patients.
Clinical Development Status
- Phase 1 trial evaluating safety and antitumor activity of escalating doses of ASG-15ME in patients with urothelial cancer
Proposed Mechanism of Action
ASG-15ME is an investigational agent, and its safety and efficacy have not yet been established.